The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome

Inclusion Criteria:

• ≥ 3 criteria for metabolic syndrome National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III criteria)
• Triglyceride (TG) < 400 mg/dl and Low Density Lipoprotein-Cholesterol (LDL-C) 100 mg/dl to 190 mg/dl
• Written informed consent for participating in the study

Exclusion Criteria:

• Severe renal disease or renal dysfunction
• Chronic liver disease or liver function impairment
• Inflammatory muscle dysfunction or findings of muscle problems
• Severe cardiac failure

Other protocol defined inclusion exclusion criteria may apply